Literature DB >> 23218935

Postoperative subcutaneous instillation of low-dose ketorolac but not hydromorphone reduces wound exudate concentrations of interleukin-6 and interleukin-10 and improves analgesia following cesarean delivery.

Brendan Carvalho1, Harry J Lemmens, Vicki Ting, Martin S Angst.   

Abstract

UNLABELLED: The objectives of this study were to test the effects of low-dose ketorolac and hydromorphone added to continuous local anesthetic wound instillation on surgical-site inflammatory mediators, postoperative pain, and opioid consumption. Sixty healthy women undergoing cesarean delivery were enrolled in this randomized, double-blinded study. Patients were randomized to receive a subcutaneous wound instillation of bupivacaine .5% at 10 mg/hour (active control), bupivacaine .5% with ketorolac .6 mg/hour, or bupivacaine .5% with hydromorphone .04 mg/hour for 48 hours postcesarean. Wound exudate was sampled at 4, 24, and 48 hours postcesarean and assayed for interleukins IL-1β, IL-2, IL-6, IL-8, IL-10, and IL-12, tumor necrosis factor (TNF-α), interferon (INF-γ), and granulocyte-macrophage colony stimulating factor (GM-CSF). The addition of ketorolac to bupivacaine significantly decreased IL-6 (P = .012) and IL-10 (P = .005) compared to plain bupivacaine. Ketorolac, but not hydromorphone, was associated with a decrease in pain (P = .018) and analgesic use (P = .020) following cesarean delivery. Our results are compatible with the view that significant analgesics effects are mediated through local modulation of inflammatory events. Low-dose ketorolac administered into surgical wounds exert significant anti-inflammatory and analgesic effects and may be a valuable analgesic alternative to systemic nonsteroidal anti-inflammatories (NSAIDs) but with potentially fewer side effects. PERSPECTIVE: This article demonstrates that low-dose ketorolac administered into wounds modulates local inflammatory events, decreases postoperative pain, and reduces opioid consumption. These results suggest that administration of NSAIDs into surgical wounds may be an analgesic alternative to higher systemic dosing of NSAIDs.
Copyright © 2013 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218935     DOI: 10.1016/j.jpain.2012.10.002

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  5 in total

1.  The role of subcutaneous ketorolac for pain management.

Authors:  Mary E Vacha; Wennie Huang; Jennifer Mando-Vandrick
Journal:  Hosp Pharm       Date:  2015-02

2.  Efficacy of continuous in-wound infusion of levobupivacaine and ketorolac for post-caesarean section analgesia: a prospective, randomised, double-blind, placebo-controlled trial.

Authors:  Jozica Wagner-Kovacec; Petra Povalej-Brzan; Dusan Mekis
Journal:  BMC Anesthesiol       Date:  2018-11-10       Impact factor: 2.217

3.  Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study.

Authors:  Guangming Yan; Jie Chen; Guiying Yang; Guangyou Duan; Zhiyong Du; Zubin Yu; Jing Peng; Wei Liao; Hong Li
Journal:  BMC Anesthesiol       Date:  2018-12-19       Impact factor: 2.217

Review 4.  Wound fluid sampling methods for proteomic studies: A scoping review.

Authors:  Joe Harvey; Kieran T Mellody; Nicky Cullum; Rachel E B Watson; Jo Dumville
Journal:  Wound Repair Regen       Date:  2022-04-05       Impact factor: 3.401

5.  Evaluation of a novel biodegradable thermosensitive keto-hydrogel for improving postoperative pain in a rat model.

Authors:  Meng-Huang Wu; Ming-Hung Shih; Wei-Bin Hsu; Navneet Kumar Dubey; Wen-Fu Lee; Tsai-Yu Lin; Meng-Yow Hsieh; Chin-Fu Chen; Kuo-Ti Peng; Tsung-Jen Huang; Chung-Sheng Shi; Ren-Shyang Guo; Chang-Jhih Cai; Chiu-Yen Chung; Chung-Hang Wong
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.